Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00103428
Status:
TERMINATED
Last Update Posted:
2006-02-02
First Post:
2005-02-08
Brief Title:
Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer
Sponsor:
Cell Genesys
Organization:
Cell Genesys
Study Overview
Official Title:
A Phase 12a Dose-Escalation Trial of Intravenous CG7870 in Combination With Docetaxel in Chemotherapy-Naïve Patients With Metastatic Hormone-Refractory Prostate Cancer
Status:
TERMINATED
Status Verified Date:
2006-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
V-0039 is a Phase 12 dose escalation trial of CG7870 in combination with Docetaxel in metastatic hormone-refractory patients who have not received chemotherapy
All patients will receive docetaxel In the dose escalation phase of the study patients will receive treatment intravenously with CG7870 at one of up to four dose levels In the Phase 2 portion of this study additional patients will be added at the maximum tolerated dose that is determined in Phase 1
All patients will receive docetaxel In the dose escalation phase of the study patients will receive treatment intravenously with CG7870 at one of up to four dose levels In the Phase 2 portion of this study additional patients will be added at the maximum tolerated dose that is determined in Phase 1
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None